<DOC>
	<DOCNO>NCT01813955</DOCNO>
	<brief_summary>Phosphodiesterase ( PDE ) inhibitor represent new group potential antipsychotic compound currently development . One papaverine , inhibitor PDE 10 family . The class PDE10 inhibitor report possible candidate treatment schizophrenia , may prove attractive antipsychotic alternative due many side-effects currently available antipsychotic . It propose preclinical study PDE10 inhibitor potential reduce cognitive deficit schizophrenia finding need confirm human population , view fact currently register drug posse unique property . The currently propose project design investigate whether PDE10 inhibitor Papaverine indeed capacity reduce cognitive deficit schizophrenia patient . In order accomplish effect , Papaverine investigate schizophrenia , regard symptomatology , hemodynamic , neurocognition early information-processing .</brief_summary>
	<brief_title>Phosphodiesterase ( PDE ) Inhibitors Effect Cognitive Deficits Associated Schizophrenia</brief_title>
	<detailed_description>The study double blind , balance crossover design . Randomized , half subject give Papaverine ( PDE10 inhibitor , 300 mg orally ) first session follow placebo second , half treat reverse order . There minimum one month two test-sessions . After two treatment , subject test psychophysiological ( Copenhagen Psychophysiological Test-Battery ) neuropsychological test-battery ( test Cambridge Neuropsychological Test Automated Battery , `` CANTAB '' ) . The project three phase : In first phase 10 healthy subject include determine kinetics Papaverine-contained release capsule ; second phase 30 schizophrenia patient 30 healthy subject include determine impact cognitive sensory gate related deficit ; Finally 10 Healthy subject include determine effect Papaverine hemodynamical parameter mean magnetic resonance scanning .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Papaverine</mesh_term>
	<criteria>Diagnosed Schizophrenia ( WHO ICD 10 ) Treatment stable ( regulation medicine 6 week prior ) Mono antipsychotic treatment No regular Antidepressants ( PN accept ) No regular Benzodiazepines ( PN accept ) Dependence syndrome Severe physical illness MRI incompatible , non removable object shoulder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>phosphodiesterase inhibitor</keyword>
	<keyword>Psychophysiology</keyword>
	<keyword>Cognition</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Papaverine</keyword>
</DOC>